Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a...


Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket.

Comments (1)
  • norjud
    , contributor
    Comments (483) | Send Message
     
    Looks like a winner. Takeda needs to go ahead and buy at this low price...ya Dig!
    24 Apr 2013, 11:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs